Editorial and scientific policy.

Educational purpose

The content explains health topics in accessible U.S. English. It does not diagnose, prescribe, or replace an individual evaluation by a licensed health care professional. Personal decisions depend on history, examination, risks, preferences, and the laws that apply where care is provided.

Source hierarchy

Priority is given to public health agencies, scientific societies, high-quality systematic reviews and meta-analyses, randomized clinical trials, and relevant observational studies. Preclinical research, case reports, opinion, and promotional materials are identified as limited evidence and do not support promises of clinical results.

Editorial evidence ratings

• Strong: convergent guidelines and robust studies applicable to the population discussed.
• Moderate: a probable benefit or association with meaningful limitations, heterogeneity, or lower certainty.
• Weak: small, indirect, observational, or inconsistent data.
• Insufficient clinical evidence: no reliable human support or recognized recommendation for the promoted routine use or claim.

This scale is an editorial communication tool; it is not a complete GRADE assessment of a narrowly framed clinical question.

Authorship, review, and updates

Each publication identifies its author and most recent review date. Content is reviewed after major guidelines, FDA or Anvisa safety communications, evidence that may change a conclusion, or a factual correction. References remain available for readers to verify.

Professional identification and jurisdiction

The content is authored by Dr. Elias Tamer Merhi Júnior, a physician registered in Goiás, Brazil (CRM-GO 14,866). He does not hold himself out as a U.S.-licensed physician, and this website does not offer medical services in the United States. Article categories describe educational subjects only; they do not advertise a board certification, specialty credential, or remote treatment service.

Brazilian medical advertising rules

Professional communication follows Brazilian Federal Council of Medicine (CFM) Resolution No. 2,336/2023, including accurate professional identification, sober language, no sensationalism, and no guarantee of results. The original Brazilian rule governs the physician’s communication.

View CFM Resolution No. 2,336/2023 (Portuguese).

Medications and products

Mentioning a drug, device, or supplement is educational and is not a prescription, advertisement, or commercial endorsement. Brand names are used only when necessary for public understanding, together with the active ingredient and without promotional advantage. U.S. pages prioritize current FDA labeling when discussing U.S. indications and warnings; Brazilian pages follow Anvisa materials.

Conflicts and independence

Commercial relationships, sponsorships, or participation in projects related to a topic must be disclosed. Sponsored material will not be presented as an independent scientific review.

Corrections and contact

Factual errors are corrected promptly. Suggestions and review requests may be submitted through the contact channels listed on this website.